[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidade Federal do Rio Grande do Norte\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":201},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,83,96,128,153,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100054040","phase-2-inhaled-dmt-for-major-depressive-disorder-100054040",false,"NCT07562191","Inhaled DMT for Major Depressive Disorder","Randomized, Double-Blind, Placebo-Controlled Phase IIb Trial of Inhaled N,N-Dimethyltryptamine (DMT) for Major Depressive Disorder","DMT-MDD","Inclusion Criteria:\n\n* 18 years or older, capable of making decisions, and able to provide informed consent.\n* Major Depressive Disorder (MDD) according to DSM-5 criteria\n* Current depressive episode of moderate to severe intensity\n* Episode duration of at least two weeks\n* Baseline MADRS score ≥ 20\n* No treatment changes (including antidepressants) in the 4 weeks prior to the study\n* Abstain from psychedelics ≥14 days before dosing (D0)\n\nExclusion criteria:\n\n* Major cardiac, hepatic, or renal disease; unstable cardiovascular conditions\n* Uncontrolled hypertension, QTc prolongation, arrhythmias, or valvular disease COPD or asthma\n* Severe obesity, uncontrolled diabetes, coagulopathy, thyroid disease, or glaucoma\n* Neurological risk (e.g., aneurysm, ↑ICP, epilepsy\u002Fseizures, severe disorders)\n* MAO deficiency or history of serotonin syndrome\n* Pregnant, breastfeeding, positive test, or no effective contraception\n* Secondary depression\n* Cluster B personality disorders (incl. borderline with ≥2 suicidal behaviors in past 12 months) or poor therapeutic rapport\n* Psychotic disorders, MDD with psychotic features, or first-degree family history of psychosis\u002Fbipolar disorder\n* Mania\u002Fhypomania\n* OCD, dissociative disorders, active PTSD, or decompensated eating disorders\n* Moderate-severe use disorder (past 6 months; except nicotine\u002Fcaffeine)\n* Lifetime ketamine, PCP, psychedelics, or MDMA use disorder\n* Current use of MAO inhibitors, unless discontinued at least 14 days prior to dosing\n* Psychedelic trial participation in past 12 months\n* Cognitive impairment affecting valid assessment","ALL","18 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This Phase 2b, randomized, double-blind, active-controlled clinical trial will evaluate the efficacy and safety of inhaled N,N-dimethyltryptamine (DMT) in adults with Major Depressive Disorder (MDD).\n\nThe study will test whether inhaled DMT can rapidly reduce depressive symptoms and suicide risk compared with a low-dose active comparator. A total of 140 participants will be randomized 1:1 to receive either 15 mg followed 1 hour later by 60 mg of inhaled DMT, or 1 mg followed 1 hour later by 4 mg of inhaled DMT.\n\nParticipants who do not achieve remission at Day 7 will enter an open-label extension and receive a high-dose DMT session on Day 14 (±3 days). All participants will be followed for up to 12 months to evaluate the durability of response, safety, functioning, and quality of life.",[27,28,29,30,31],"MDD","Major Depressive Disorder (MDD)","Major Depression","Suicidal Ideation","Suicide",[33,34,35,36,37,38,39,40],"DMT","major depressive disorder","N,N-dimethyltryptamine","psychedelic therapy","inhaled DMT","vaporized DMT","suicidality","non invasive","RECRUITING","2026-07-09",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":21},"2026-08-01",{"date":49,"type":21},"2027-08-01",{"name":51,"class":52},"Universidade Federal do Rio Grande do Norte","OTHER",5,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100571414","phase-2-hd-tdcs-in-amyotrophic-lateral-sclerosis-a-multicenter-randomized-controlled-trial-100571414","NCT06719947","HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial","High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial","tDCS-ALS","Inclusion Criteria:\n\n* Both sexes; diagnosis of ALS according to the revised El Escorial criteria;\n* Age between 18 and 80 years;\n* Forced Vital Capacity greater than 50% of predicted;\n* Sniff nasal inspiratory pressure greater than 40 cmH2O;\n* A telephone number to contact the care team and who signed the study consent form.\n\nExclusion Criteria:\n\n* Subjects who are unable to understand or perform any of the study procedures;\n* Subjects who do not agree to participate or voluntarily request withdrawal from the study at any time;\n* Subjects with cardiac, respiratory, or musculoskeletal comorbidities;\n* Subjects using invasive mechanical ventilation;\n* Subjects with a tracheostomy;\n* Subjects with a pacemaker;\n* Subjects with metallic brain implants or other electronic implants;\n* Subjects with a cochlear implant;\n* Subjects with epileptic activity or a history of epilepsy, or a family history of epilepsy;\n* Subjects with a history of stroke or tumor;\n* Subjects prone to severe hemodynamic fluctuations, acute infectious processes, and\u002For inflammatory conditions;\n* Pregnant women at the time of recruitment;\n* Subjects who are unable to complete the intervention protocol.","80 Years",{"count":64,"type":21},80,[24,66],"PHASE3","Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality. Studies suggest that High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a technique for modulating motor cortical hyperexcitability. However, evidence on the use of HD-tDCS as a neuromodulator of the diaphragmatic motor cortex in people with ALS is inconclusive.",[69],"Amyotrophic Lateral Sclerosis (ALS)",[69,71,72,73],"Central Nervous System Diseases","Electric Stimulation Therapy","Transcranial Direct Current Stimulation","2026-06-25",{"date":76,"type":45},"2026-06-29",{"date":78,"type":45},"2025-11-28",{"date":80,"type":21},"2028-09-01",{"name":51,"class":52},4,{"id":84,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":25,"conditions":88,"keywords":89,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":95,"locationsCount":53},"100636169","Inclusion Criteria:\n\n* 18 years or older, capable of making decisions, and able to provide informed consent.\n* Major Depressive Disorder (MDD) according to DSM-5 criteria\n* Current depressive episode of moderate to severe intensity\n* Episode duration of at least two weeks\n* Baseline MADRS score ≥ 20\n* No treatment changes (including antidepressants) in the 4 weeks prior to the study\n* Abstain from psychedelics ≥14 days before dosing (D0) and during the 12-month follow-up\n\nExclusion criteria:\n\n* Major cardiac, hepatic, or renal disease; unstable cardiovascular conditions\n* Uncontrolled hypertension, QTc prolongation, arrhythmias, or valvular disease COPD or asthma\n* Severe obesity, uncontrolled diabetes, coagulopathy, thyroid disease, or glaucoma\n* Neurological risk (e.g., aneurysm, ↑ICP, epilepsy\u002Fseizures, severe disorders)\n* MAO deficiency or history of serotonin syndrome\n* Pregnant, breastfeeding, positive test, or no effective contraception\n* Secondary depression\n* Cluster B personality disorders (incl. borderline with ≥2 suicidal behaviors in past 12 months) or poor therapeutic rapport\n* Psychotic disorders, MDD with psychotic features, or first-degree family history of psychosis\u002Fbipolar disorder\n* Mania\u002Fhypomania (YMRS ≥8)\n* OCD, dissociative disorders, active PTSD, or decompensated eating disorders\n* Moderate-severe use disorder (past 6 months; except nicotine\u002Fcaffeine)\n* Lifetime ketamine, PCP, psychedelics, or MDMA use disorder\n* Current use of MAO inhibitors, unless discontinued at least 14 days prior to dosing\n* Psychedelic trial participation in past 12 months\n* Cognitive impairment affecting valid assessment",{"count":20,"type":21},[24],[27,28,29,30,31],[33,34,35,36,37,38,39,40],"2026-05-22",{"date":92,"type":45},"2026-05-28",{"date":47,"type":21},{"date":49,"type":21},{"name":51,"class":52},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":107,"conditions":108,"keywords":114,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100600592","reduced-functionality-and-kinesiophobia-in-patients-with-heart-failure-use-of-alternative-therapeutic-strategies-100600592","NCT07099495","REDUCED FUNCTIONALITY AND KINESIOPHOBIA IN PATIENTS WITH HEART FAILURE: USE OF ALTERNATIVE THERAPEUTIC STRATEGIES","Reduced Functionality and Kinesiophobia in Patients With Heart Failure: Use of Neuromuscular Electrical Stimulation as an Alternative Therapeutic Strategy","Inclusion Criteria:\n\n* Individuals of both sexes;\n* Age ≥ 18 years;\n* Diagnosis of chronic HF;\n* Symptoms compatible with Functional Class (FC) III-IV of the New York Heart Association (NYHA);\n* Stable condition on pharmacological therapy;\n* Absence of Acute Myocardial Infarction in the last three months prior to participant recruitment;\n* Absence of an automatic internal cardioverter defibrillator (ICD) or cardiac pacemaker;\n\nExclusion Criteria:\n\n* Individuals with hemodynamic instability, unstable angina, acute myocardial infarction during the period of application of the protocol and diagnosis of hypertrophic cardiomyopathy during the period of application of the protocol;\n* Individuals with recent muscle or tendon injuries, muscular dystrophies, myopathies, unstable fractures, infections or deep vein thrombosis (DVT);\n* Chronic need for oxygen therapy;\n* Absence in reassessments;\n* Refusal to participate in the research after its beginning.",{"count":104,"type":21},54,[106],"NA","Introduction: Heart failure (HF) is a clinical syndrome that has advanced on a large scale concomitant with population aging and other factors. Thus, the search for alternatives that minimize the losses resulting from its structural and functional damage are important to optimize its treatments, with the primary objective of enabling the participation of these individuals in the most diverse daily tasks. Low-frequency (LF) or medium-frequency (MF) neuromuscular electrical stimulation (NMES) can be considered a resource to enable the improvement of vital and functional parameters of the population with HF intolerant to physical exercise, and it is also important to identify within these modalities which is most effective. In addition to these factors, kinesiophobia can be found in this population, and NMES can also be adopted as a strategy for kinesiophobia in these patients, with the objective of enabling the progression of behaviors. Objective: To evaluate and compare the effectiveness of LF and MF NMES on the indices of kinesiophobia and functionality in patients with HF. Methods: The research will be divided into two types of study: a double-blind randomized clinical trial (RCT) to evaluate NMES protocols, and a qualitative study with subsequent development and validation of a questionnaire to measure kinesiophobia in individuals with HF. The population included in the RCT will have their assessments (personal, socioeconomic, demographic data, Sit-to-Stand Test, kinesiological ultrasound and surface electromyography of the quadriceps muscles) conducted before their discharge from Hospital Nova Esperança (HNE), and after completion of the protocols at the same institution, in the city of João Pessoa - Paraíba. The application of NMES protocols will be carried out in the home environment (30 min\u002Fday, 3 times a week, for a total of 8 consecutive weeks). The population for the qualitative study and for the development of the questionnaire will consist of individuals diagnosed with HF of any etiology, compensated and able to perform kinesiotherapy activities, admitted to the HNE wards, between 24-48 hours before hospital discharge. An in-depth semi-structured interview will be conducted with these individuals, followed by the application of questionnaires developed based on the interviews, and the entire study will be conducted while the patients are hospitalized. Expected results: Regarding the first study, it is expected that patients treated with NMES will show improvements in clinical and functional variables, and these improvements may be more pronounced depending on the frequency applied. On the other hand, the qualitative study may reveal whether patients have fear of movement, even if they are clinically stable. The developed questionnaire will be well understood and have adequate psychometric qualities. Finally, it is expected that this knowledge can serve as a basis for optimizing the care of this patient population.",[109,110,111,112,113],"Heart Failure","Heart Failure NYHA Class III","Heart Failure NYHA Class IV","Neuromuscular Electrical Stimulation (NMES)","Kinesiophobia",[115,116,117],"heart failure","neuromuscular electrical stimulation","kinesiophobia","NOT_YET_RECRUITING","2025-07-24",{"date":121,"type":45},"2025-08-01",{"date":123,"type":21},"2025-08-18",{"date":125,"type":21},"2027-12-30",{"name":51,"class":52},1,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":135,"minAge":18,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":127},"100548726","preference-of-women-with-fibromyalgia-undergoing-a-three-different-volumes-of-resistance-training-100548726","NCT06424743","Preference of Women With Fibromyalgia Undergoing a Three Different Volumes of Resistance Training","Preference of Women With Fibromyalgia Undergoing a Three Different Volumes of Resistance Training: Clinical Trial Randomized Crossover","Inclusion Criteria:\n\n* Women aged 18 to 65\n* Have a diagnosis of fibromyalgia according to the ACR 2016 criteria\n\nExclusion Criteria:\n\n* Have performed resistance training in the last 6 months\n* Having another associated rheumatic condition\n* Have a trip or appointment scheduled that requires absence for the next 4 (four) weeks from the start of the survey;\n* Women with musculoskeletal injuries in the upper and\u002For lower limbs\n* Have heart problems that prevent maximal efforts and submaximums","FEMALE","65 Years",{"count":138,"type":21},36,[106],"Fibromyalgia is a painful syndrome of unknown etiology, which affects 2% of world population, with symptoms such as: pain, unrefreshing sleep, fatigue and mood disorders. It is already established in the literature that resistance training is part of the non- pharmacological treatment for patients with fibromyalgia. The big gap is about the quantity adequate and\u002For recommended exercise volume, despite some studies with exercise volumes different resistance trainings show improvements, we do not have a direction, besides We still do not know whether there is a preference for these patients in different resistance training volumes.",[142,143,144],"Fibromyalgia, Primary","Chronic Pain","Exercise Addiction","2025-07-19",{"date":147,"type":45},"2025-07-23",{"date":149,"type":45},"2025-07-01",{"date":151,"type":21},"2026-12-01",{"name":51,"class":52},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":127},"100474551","effect-of-dry-cupping-therapy-associated-with-the-mckenzie-method-in-patients-with-chronic-low-back-pain-100474551","NCT05459376","Effect of Dry Cupping Therapy Associated With the McKenzie Method in Patients With Chronic Low Back Pain","Effect of Dry Cupping Therapy Associated With the McKenzie Method in Patients With Chronic Low Back Pain: Protocol for a Sham-controlled Randomized Trial","MDTDryCup","Inclusion Criteria:\n\n* Individuals, male and female, 18 to 59 years, non-obese, with non-specific localized LBP for more than 3 months;\n* Report pain intensity between 3 and 8 according to the numerical pain scale;\n\nExclusion Criteria:\n\n* Have previously performed cupping therapy in some body segment;\n* Present neurological, vestibular, visual or auditory deficits that make assessments impossible;\n* Being in the gestational period;\n* Having severe spinal disease (including fractures, tumour, inflammatory diseases, or tumours);\n* Have undergone previous spinal surgery;\n* Present with radiating or sacroiliac back pain; another rheumatic disease such as fibromyalgia,or ankylosing spondylitis.","59 Years",{"count":64,"type":21},[106],"Introduction: Currently, clinical practice guidelines recommend exercise as a first-line approach to the treatment of chronic low back pain (LBP). On the other hand, passive techniques such as cupping therapy have gained space in the management of this population, however, important gaps regarding the combination of cupping therapy with active exercises in individuals with nonspecific chronic low back pain are still present in the literature. In this context, this protocol describes a sham-controlled, randomized and blinded study that aims to evaluate the additional effects of cupping therapy in association with McKenzie method exercises on pain and functional outcomes of individuals with nonspecific chronic low back pain. Methods: 108 individuals with nonspecific and localized chronic low back pain in the age group of 18 to 59 years will be recruited and evaluated, regarding the inclusion and exclusion criteria. Subsequently, they will be randomized to one of 2 groups: intervention group, in which they will be submitted to the McKenzie method intervention and later the addition of the dry suction cup; and sham group, in which, after the intervention of the McKenzie method, the application of the sham cup will be added.",[166],"Low Back Pain","2025-04-01",{"date":169,"type":45},"2025-04-02",{"date":171,"type":21},"2026-01-01",{"date":173,"type":21},"2028-01-01",{"name":51,"class":52},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":136,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":191,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":127},"100298897","addition-of-proprioceptive-neuromuscular-facilitation-to-cardio-respiratory-training-post-stroke-100298897","NCT03171012","Addition of Proprioceptive Neuromuscular Facilitation to Cardio Respiratory Training Post Stroke","Proprioceptive Neuromuscular Facilitation Repercussions Associated With Cardiorespiratory Training in Postal Individuals Stroke to the Functions Motor, Respiratory and Quality of Life: Randomized Controlled Trial","Inclusion Criteria:\n\n* Have clinical diagnosis of ischemic or hemorrhagic stroke,\n* primary for more than six months resulting in hemiparesis;\n* Have mental competence assessed through the Mini-Exam of the Mental State-MMSE;\n* Be able to walk 10 meters independently, with or without assistive device;\n* Absence of other neurological or orthopedic deficiencies unrelated to stroke;\n* Without report of associated pulmonary pathology and not be smoker or ex-smoker.\n\nExclusion Criteria:\n\n\\-","21 Years",{"count":184,"type":21},40,[106],"Post-stroke hemiparesis causes sequelae in the limbs and also in the trunk and abdomen structures. The level of physical activity decreases and cardiorespiratory training(CRT) is indicated to this population to improve the functions of several systems (respiratory, cardiovascular, muscular). The application of Proprioceptive Neuromuscular Facility(PNF) would imply in the awareness and greater harmony of the functions performed by the trunk of this individual. The objective of this study is to evaluate the effects of respiratory and trunk characteristics of the PNF associated with Cardiorespiratory training in quality of life, gait, distance traveled, peak oxygen consumption, respiratory muscle strength, thoracic cavity volumes, mobility and diaphragmatic thickness of individuals with post stroke.",[188,189,190],"Stroke","Chest Wall Disorder","Quality of Life",[192],"Muscle Stretching Exercises","2023-05-09",{"date":195,"type":45},"2023-05-11",{"date":197,"type":45},"2017-06-19",{"date":199,"type":21},"2026-06",{"name":51,"class":52},""]